商品编号


G3101



品牌


UBPBio



公司


Ubiquitin-Proteasome Biotechnologies, LLC



公司分类


Fluorescent Peptide / Protein Substrates



Size

25 mg

商品信息

Boc-LRR-AMC is a fluorogenic substrate for the trypsin – like activity of the 20S proteasome. Working concentrations of this substrate is 50-200 ?M. The released AMC can be detected by a fluorimeter or plate reader at excitation/emission wavelengths of 380 nm/460 nm, respectively.

When used to determine proteasome activity in cell lysates, cell lysates that are pre-treated with a proteasome inhibitor such as MG132, PS341 or epoxomicin can be used to determine the fluorescence contributed by other cellular proteases that cleave this substrate. Re
ADI
ngs from proteasome inhibitor-treated lysates should be subtracted.

Additional Information






Product Name:

Boc-Leu-Arg-Arg-AMC (Boc-LRR-AMC)



Also Known As:

Boc-LRR-AMC



Catalog No.:

G3101



Size:

25 mg



Molecular Weight:

773.8 Da



Species:

N/A



Source:

Synthetic



Stock:

Powder



Concentration:

N/A



Quality Assurance:

>98% by HPLC and NMR



Storage:

Elig
IBL
e for room temperature shipping. Store at -80°C upon receiving; avoid multiple freeze-thaw cycles after dissolving in DMSO.



PDF Data Sheet:

Download PDF datasheet



NCBI RefSeq:

N/A



Image(s):

No



Shipping Method:

Room temperature shipping



References:

1. Chen P,
et al
. (1996) Cell 86(6), 961 – 972.
2. Arendt CS,
et al
. (1997) Proc Natl Acad Sci 94(14), 7156 – 7161. 3. Reidlinger J,
et al
. (1997) J Biol Chem 272(40), 24899 – 24905.




Details

Boc-LRR-AMC is a fluorogenic substrate for the trypsin – like activity of the 20S proteasome. Working concentrations of this substrate is 50-200 ?M. The released AMC can be detected by a fluorimeter or plate reader at excitation/emission wavelengths of 380 nm/460 nm, respectively. When used to determine proteasome activity in cell lysates, cell lysates that are pre-treated with a proteasome inhibitor such as MG132, PS341 or epoxomicin can be used to determine the fluorescence contributed by other cellular proteases that cleave this substrate. Re
ADI
ngs from proteasome inhibitor-treated lysates should be subtracted.